| 24/06/2026 | UBS Group AG | 1213(L) | -4,574,000(L) | | 172,627,945(L) 32,758,602(S) | 5.85 1.11 | | 15/06/2026 | UBS Group AG | 1316(L) | 5,278,184(L) | | 181,882,945(L) 32,723,602(S) | 6.16 1.11 | | 22/05/2026 | UBS Group AG | 1402(S) | +417,000(S) | | 191,143,845(L) 29,636,502(S) | 6.48 1.00 | | 21/05/2026 | 曲繼廣 | 1113(L) | +1,300,000(L) | HKD 2.373(L) | 1,262,492,000(L) | 42.78 | | 20/05/2026 | 曲繼廣 | 1113(L) | +2,000,000(L) | HKD 2.313(L) | 1,261,192,000(L) | 42.73 | | 19/05/2026 | 曲繼廣 | 1113(L) | +2,000,000(L) | HKD 2.353(L) | 1,259,192,000(L) | 42.66 | | 18/05/2026 | 曲繼廣 | 1113(L) | +2,500,000(L) | HKD 2.330(L) | 1,257,192,000(L) | 42.60 | | 05/05/2026 | China Pharmaceutical Company Limited | 1710(L) | +1,100,000(L) | HKD 2.353(L) | 911,604,000(L) | 30.89 | | 05/05/2026 | 曲繼廣 | 1113(L) | +1,100,000(L) | HKD 2.353(L) | 1,254,692,000(L) | 42.51 | | 17/04/2026 | 曲繼廣 | 1113(L) | +1,450,000(L) | HKD 2.497(L) | 1,253,592,000(L) | 42.48 | | 17/04/2026 | China Pharmaceutical Company Limited | 1710(L) | +1,450,000(L) | HKD 2.497(L) | 910,504,000(L) | 30.85 | | 16/04/2026 | 曲繼廣 | 1113(L) | +1,450,000(L) | HKD 2.512(L) | 1,252,142,000(L) | 42.43 | | 16/04/2026 | China Pharmaceutical Company Limited | 1710(L) | +1,450,000(L) | HKD 2.512(L) | 909,054,000(L) | 30.80 | | 10/04/2026 | China Pharmaceutical Company Limited | 1710(L) | +1,800,000(L) | HKD 2.545(L) | 907,604,000(L) | 30.75 | | 10/04/2026 | 曲繼廣 | 1113(L) | +1,800,000(L) | HKD 2.545(L) | 1,250,692,000(L) | 42.38 | | 09/04/2026 | China Pharmaceutical Company Limited | 1710(L) | +3,000,000(L) | HKD 2.515(L) | 905,804,000(L) | 30.69 | | 09/04/2026 | 曲繼廣 | 1113(L) | +3,000,000(L) | HKD 2.515(L) | 1,248,892,000(L) | 42.32 | | 08/04/2026 | 曲繼廣 | 1113(L) | +4,200,000(L) | HKD 2.512(L) | 1,245,892,000(L) | 42.21 | | 08/04/2026 | China Pharmaceutical Company Limited | 1710(L) | +4,200,000(L) | HKD 2.512(L) | 902,804,000(L) | 30.59 | | 01/04/2026 | 曲繼廣 | 1113(L) | +4,300,000(L) | HKD 2.513(L) | 1,241,692,000(L) | 42.07 | | 01/04/2026 | China Pharmaceutical Company Limited | 1710(L) | +4,300,000(L) | HKD 2.513(L) | 898,604,000(L) | 30.45 | | 31/03/2026 | 曲繼廣 | 1113(L) | +4,100,000(L) | HKD 2.511(L) | 1,237,392,000(L) | 41.93 | | 31/03/2026 | UBS Group AG | 1113(L) | +5,097,022(L) | | 180,934,736(L) | 6.13 | | 31/03/2026 | China Pharmaceutical Company Limited | 1710(L) | +4,100,000(L) | HKD 2.511(L) | 894,304,000(L) | 30.30 | | 27/03/2026 | 周興揚 | 1711(L) | -2,000,000(L) | | 0(L) | 0.00 | | 27/03/2026 | 孟國 | 1711(L) | -20,000,000(L) | | 0(L) | 0.00 | | 27/03/2026 | UBS Group AG | 1314(L) | 1,784,000(L) | | 167,710,802(L) | 5.68 | | 19/03/2026 | 四川科倫藥業股份有限公司 | 1711(L) | 468,296,000(L) | | 680,686,000(L) | 23.07 | | 10/03/2026 | UBS Group AG | 1213(L) | -13,317,171(L) | | 165,156,131(L) | 5.60 | | 05/03/2026 | UBS Group AG | 1313(L) | 7,980,000(L) | | 184,640,893(L) | 6.26 | | 27/02/2026 | UBS Group AG | 1313(L) | 6,104,000(L) | | 185,008,997(L) | 6.27 | | 25/02/2026 | UBS Group AG | 1313(L) | 3,224,900(L) | | 184,940,486(L) | 6.27 | | 05/02/2026 | UBS Group AG | 1502(S) | -1,456,000(S) | | 184,114,599(L) 28,228,032(S) | 6.35 0.97 | | 19/01/2026 | UBS Group AG | 1402(S) | +394,800(S) | | 185,359,396(L) 29,310,829(S) | 6.39 1.01 | | 14/01/2026 | UBS Group AG | 1502(S) | -744,000(S) | | 184,952,596(L) 28,556,029(S) | 6.38 0.98 | | 09/01/2026 | 曲繼廣 | 1113(L) | +456,000(L) | HKD 3.045(L) | 1,233,292,000(L) | 41.79 | | 08/01/2026 | 曲繼廣 | 1113(L) | +1,486,000(L) | HKD 3.043(L) | 1,232,836,000(L) | 41.77 | | 07/01/2026 | 曲繼廣 | 1113(L) | +1,128,000(L) | HKD 3.020(L) | 1,231,350,000(L) | 41.72 | | 06/01/2026 | 曲繼廣 | 1113(L) | +1,500,000(L) | HKD 2.980(L) | 1,230,222,000(L) | 41.68 | | 05/01/2026 | 曲繼廣 | 1113(L) | +1,100,000(L) | HKD 2.898(L) | 1,228,722,000(L) | 41.63 | | | 1 2 3 4 5 |
|